AR and prostate carcinoma: Altogether, our findings suggest that p300/CBP complexes retain their acetyltransferase activity for the H2BNT lysine residues despite the attenuation of the reader bromodomain, which sustains AR enhancer activity and triggers a distinct oncogenic gene program in prostate cancer cells.